Nasdaq OMX

Crown Bioscience Inc.

Del

Crown Bioscience Showcases Dramatic Proficiency in PDX Models and Emerging Expertise in Immune-Oncology

Post AACR Immuno-Oncology Scientific Advancements

SANTA CLARA, Calif., June 01, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience , a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research, announces depth and breadth of technologies that ignite and accelerate the development of new immune-oncology drug discovery.

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/71dfadf0-8256-43cd-bafb-c429a8d37457

CrownBio scientific contribution to AACR:

  • Technology which engrafts human immune cells into immunocompromised animals. When tested with immune activating agents, both short-term (PBMC) and long-term (CD34+ stem cell) engraftment strategies demonstrate robust anticancer activity. 

  • Syngeneic models - both in vitro  and in vivo  data utilizing their MuScreen(TM) platform, a large panel of well-characterized and validated syngeneic models, employed to test the activity of immune modulating anticancer drugs.

  • Utilization of RNASeq data providing expression and mutation data from 18 cell lines. Investigators leverage this data to test both targeted therapy and immune-modulatory therapy in combination, thus providing rationale for clinical investigation.

  • In vivo , the MuScreen platform enables an agnostic investigation of a compound's activity and mechanism of action. MuScreen data can be followed-up with additional pharmacology studies, such as immunophenotyping, or bioluminescent assessment of metastatic burden.

"Our diligent focus on innovation, and continued scientific advancement charter unprecedented discovery in our immuno-oncology portfolio," said Jean-Pierre Wery, CEO of CrownBio. "The robust contribution at this year's annual meeting of the American Association for Cancer Research, on the part of our scientific team, validates an unwavering commitment to develop therapies that will impact the way cancer is treated."

CrownBio can be located at ASCO Booth #17071. To schedule a meeting with our scientific leadership visit: https://www.crownbio.com/asco-meeting-req

For more information on CrownBio's commitment to furthering the field of oncology and metabolic disease drug discovery, visit https://www.crownbio.com .

About Crown Bioscience Inc.

Crown Bioscience  is a global drug discovery and development solutions company providing translational platforms to advance oncology and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.

Media Enquiries:
Jody Barbeau
Crown Bioscience Inc. marketing@crownbio.com

WEB:

Information om Nasdaq OMX

Nasdaq OMX
Nasdaq OMX
Nikolaj Plads 6
1007 København K

+45 3377 0377http://globenewswire.com